Ep 52: COLUMBUS 7-year follow-up

SummaryIn this episode of Melanoma Matters, James tells us about his path to oncology (thank you, Emma) via John Newsom-Davis, the Jeremy Bentham pub, and Hammersmith Hospital.Later, hosts Sapna Patel and James Larkin discuss the COLUMBUS 7-year data of targeted therapy for metastatic melanoma - treatment efficacy, toxicity, and long-term patient management. They explore the nuances of treatment strategies, the importance of biomarkers, and the challenges of monitoring long-term patients on targeted therapies.TakeawaysTime to next therapy is a valuable metric for assessing treatment success.Long-term treatment decisions should consider patient quality of life.Biomarkers are crucial for determining the duration of targeted therapy.Compliance in clinical trials may not reflect real-world scenarios.Monitoring for long-term toxicity is necessary for patients on extended therapy.The combination of BRAF and MEK inhibitors may improve tolerability despite the COLUMBUS study showing a higher toxicity rate in the combination arm.Congratulations to the European colleagues who led and executed this trial.KeywordsBRAF MEK, targeted therapy, COLUMBUS study, melanoma, treatment efficacy, toxicity, long-term care, patient managementTitlesExploring the COLUMBUS 7-Year DataOncology Journeys: Personal Stories and InsightsSound Bites"We need to know even the low-grade toxicities.""There's nothing wrong with improving side effects.""Kudos to our mainland European colleagues."Chapters00:00 Introduction 06:12 COLUMBUS 7-Year Overview12:15 Historical context on study arms17:55 Long-Term Treatment Considerations21:29 Desperate... for a Biomarker23:43 Any insights into development of CNS disease?30:47 Fact Check for COLUMBUS 7-Year follow-up32:50 Time to End of Next Line of Treatment in COLUMBUS (akin to PFS2)35:32 Toxicity & Discontinuation Rate in COLUMBUS